Where science powers start-ups
New biotech hub BioLabs|TUM launched to foster start-ups
TUM Venture Labs, BioLabs and Eli Lilly and Company (Lilly) today launched BioLabs|TUM, a new biotechnology innovation hub in central Munich. The initiative aims to empower early-stage biotech start-ups by providing access to state-of-the-art lab infrastructure, expert mentoring, and global industry networks.
Located in a refurbished 1,800-square-meter facility, BioLabs|TUM will offer fully equipped laboratories and office space for 15–20 start-ups. The hub is designed to accelerate the development of breakthrough therapies by connecting scientific talent with venture capital and pharmaceutical expertise.
“We are thrilled to announce this collaboration with TUM Venture Labs and Lilly to launch BioLabs|TUM in Munich – marking a major milestone in expanding our innovation ecosystem in Germany,” said Johannes Fruehauf, MD, PhD, Founder & CEO of BioLabs. “With world-class science, top academic institutions, and rising investor interest, Munich is the ideal launchpad for the next generation of biotech entrepreneurs.”
The collaboration brings together BioLabs’ proven coworking lab model, TUM Venture Labs’ academic innovation engine, and Lilly’s global R&D and venture capital reach. Start-ups selected for the program will benefit from tailored programming, strategic guidance, and access to Lilly’s scientific experts.
“World-class infrastructure”
“This partnership strengthens our mission to translate cutting-edge research into real-world impact,” said Dr. Philipp Gerbert, CEO of TUM Venture Labs. “BioLabs|TUM adds world-class infrastructure and global connectivity to our vibrant startup ecosystem. The initiative reflects our shared commitment to translating scientific excellence into entrepreneurial success.”
“BioLabs|TUM is an exciting and unique collaboration, which supercharges our collective experience of catalyzing scientific innovation and empowering emerging biotech companies to navigate the complexities of therapeutic discovery and development,” said Julie Gilmore, Ph.D., Vice President and Global Head, Lilly Gateway Labs. “Lilly’s investment in BioLabs |TUM, through our Catalyze360 model, enables us to partner on our shared passion for creating bold scientific breakthroughs. Munich's robust scientific community and strong academic institutions make it an ideal location for fostering early-stage innovation and helping to accelerate the development of innovative therapies that can make a meaningful difference for patients in Germany and around the world.”
BioLabs|TUM is anticipated to open in early 2026.
Other news from the department business & finance
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.